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Abstract: Introduction
The aim of the study was to build a model of first failure site and lesion specific failure
probability after definitive chemo-radiotherapy for inoperable non-small cell lung cancer
(NSCLC).
Methods
We retrospectively analyzed 251 patients receiving definitive chemo/radiotherapy for
NSCLC at a single institution between 2009-2015. All patients were FDG PET/CT
scanned for radiotherapy planning. Clinical patient data and FDG PET standardized
uptake values from primary tumor and nodal lesions were analyzed using multivariate
cause-specific Cox regression. In patients experiencing loco-regional failure,
multivariable logistic regression was applied to assess risk of each lesion being first
site of failure. The two models were used in combination to predict lesion failure
probability accounting for competing events.
Results
Adenocarcinoma had a lower hazard ratio (HR) of loco-regional (LR) failure than
squamous cell carcinoma, HR 0.45, 95% CI [0.26; 0.76], p =0.003. Distant failures
were more common in the adenocarcinoma group, HR 2.21, 95% CI [1.41; 3.48],
p<0.001. Multivariable logistic regression of individual lesions at the time of first failure
showed primary tumors were more likely to fail than lymph nodes, OR 12.8, 95% CI
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
[5.10; 32.17], p<0.001. Increasing SUVpeak was significantly associated with lesion
failure, OR 1.26 per unit increase, 95% CI [1.12; 1.40], p<0.001. Electronic model:
http://bit.ly/LungModelFDG.
Conclusions
We developed a failure-site specific competing risk model based on patient- and
lesion-level characteristics. Failure patterns differed between adenocarcinoma and
squamous cell carcinoma, illustrating the limitation of aggregating them into 'non-small-
cell lung cancer'. Failure site specific models add complementary information to
conventional prognostic models.
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               Copenhagen, November 9th, 2017 
Dear Editor 
Attached, please find our manuscript “A competing risk model of first failure site after definitive 
(chemo) radiation therapy for locally advanced non-small cell lung cancer” 
We hereby present to you our study on 251 lung cancer patients with PET/CT workup and treated 
with radiotherapy between 2009-2015.  We have performed competing risk analysis on a patient 
and lesion level using the clinical data and FDG PET/CT uptake metrics. Failure patterns differed 
between adenocarcinoma and squamous cell carcinoma, illustrating the limitation of aggregating 
them into 'non-small-cell lung cancer'. We were able to provide a - to our knowledge - first example 
of individual risk prediction of first failure site, also within the treated volume. We propose that 
such failure site specific models add complementary information to conventional prognostic 
models. Further to the paper description of the models, we publish electronic web applications as 
supplements, see http://bit.ly/LungModelFDG. 
We trust you will find this paper of interest for the readership of Journal of Thoracic Oncology and 
we hope you will consider our research article for publication.  
All authors of this paper have directly participated in the planning, execution, and analysis of the 
study. The corresponding author confirms that she had full access to all the data and takes final 
responsibility for the submission of this manuscript.  
As stated in the manuscript, the study was approved by the Danish Health and Medicines Authority, 
case no 3-3013-569/1/ and complied with national data protection regulations.  According to Danish 
law, no research ethics approval was necessary due to the retrospective nature of the study. 
There have not been any prior interactions with JTO regarding this manuscript and it will not be 
copyrighted, submitted, or published elsewhere while acceptance by your journal is under 
consideration. 
On behalf of all authors, 
Yours sincerely, 
Lotte Nygård, MD. 
Department of Clinical Oncology 
Rigshospitalet, Blegdamsvej 9, 3994 
Cover Letter
2100 Copenhagen, Denmark 
E-mail: lotte.nygaard@regionh.dk 
Telephone: +45 3545 8877 
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Introduction 
The aim of the study was to build a model of first failure site and lesion specific failure probability 
after definitive chemo-radiotherapy for inoperable non-small cell lung cancer (NSCLC).  
Methods 
We retrospectively analyzed 251 patients receiving definitive chemo/radiotherapy for NSCLC at a 
single institution between 2009-2015. All patients were FDG PET/CT scanned for radiotherapy 
planning. Clinical patient data and FDG PET standardized uptake values from primary tumor and 
nodal lesions were analyzed using multivariate cause-specific Cox regression. In patients 
experiencing loco-regional failure, multivariable logistic regression was applied to assess risk of 
each lesion being first site of failure. The two models were used in combination to predict lesion 
failure probability accounting for competing events. 
Results 
Adenocarcinoma had a lower hazard ratio (HR) of loco-regional (LR) failure than squamous cell 
carcinoma, HR 0.45, 95% CI [0.26; 0.76], p =0.003. Distant failures were more common in the 
adenocarcinoma group, HR 2.21, 95% CI [1.41; 3.48], p<0.001. Multivariable logistic regression of 
individual lesions at the time of first failure showed primary tumors were more likely to fail than 
lymph nodes, OR 12.8, 95% CI [5.10; 32.17], p<0.001. Increasing SUVpeak was significantly 
associated with lesion failure, OR 1.26 per unit increase, 95% CI [1.12; 1.40], p<0.001. Electronic 
model: http://bit.ly/LungModelFDG. 
Conclusions  
We developed a failure-site specific competing risk model based on patient- and lesion-level 
characteristics. Failure patterns differed between adenocarcinoma and squamous cell carcinoma, 
illustrating the limitation of aggregating them into 'non-small-cell lung cancer'. Failure site specific 
models add complementary information to conventional prognostic models.  
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1. INTRODUCTION 
 
Curative intended chemo-radiotherapy has long been standard of care for inoperable non-small cell 
lung cancer patients1. Local or distant progression is frequently seen after therapy, but also death 
due to competing events is relatively frequent. Despite advances in targeted therapy for a subset of 
patients with relatively rare genetic mutations, five-year overall survival rates remain 
unsatisfactory, around 15% 2,3. The natural course of disease depends on histology, with 
adenocarcinoma (AC)  metastasizing to the brain more often than squamous cell carcinoma (SCC) 
4,5,6,7. Nevertheless, adenocarcinoma and squamous cell carcinoma are often lumped together as 
'non-small-cell lung cancer' in clinical trials or treatment guidelines. 
The Union for International Cancer Control (UICC) TNM  classifications8,9 provide important 
prognostic information.  However, when deciding on a combination of systemic and local therapies, 
estimating the risk of loco-regional versus distant recurrence separately would be of obvious 
clinical interest. Other factors such as tumor volume and number of fluoro-deoxy-glucose/positron 
emission tomography (FDG-PET) positive lymph nodes have been proposed to improve the pre-
treatment prognostic assessment10,11.   
Clinical radiotherapy trials have tested dose escalation to the primary lung tumor in an attempt to 
improve local control and in turn overall survival. However, the large RTOG 0617 randomized 
trial12 found no clinical benefit  in the dose-escalation arm emphasizing that local intensification 
may not be a viable strategy for all NSCLC patients. Improved knowledge of the most likely failure 
sites within a patient may be of relevance for further individualization of treatment options in the 
future.  
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The aim of the current study was to establish a model of the failure patterns on a patient and lesion 
level using baseline clinical data and FDG-PET/ computed tomography (CT) scans.  
2. MATERIALS AND METHODS 
 
Patients 
 
Data were retrospectively retrieved from medical records and archived scans from consecutive 
patients diagnosed with inoperable, locally advanced NSCLC and treated at Rigshospitalet, 
Copenhagen University Hospital from January 2009 to February 2015. In this time period, 
operability was determined according to clinical stage below IIIAN2, co-morbidity of the patient 
and lung function by a multidisciplinary tumor board consisting of pulmonologists, thoracic 
surgeons and medical/radiation oncologists. Patients received definitive chemo/radiotherapy or 
radiotherapy alone. Chemotherapy was either given sequentially prior to radiation or concomitantly 
with the first cycle of chemotherapy prior to the PET/CT planning scan. Chemotherapy regimens 
consisted of either cisplatin/vinorelbin or carboplatin/vinorelbin in a three-week schedule, given 
three to six times. Patients with prior early-stage lung cancer treated with surgery but now 
candidates for concomitant chemo/radiotherapy (cCRT) were also included in the study. This could 
for example be due to relapse in a lymph node station or a new primary tumor These patients were 
restaged according to the 7th TNM classification from UICC8.  
FDG-PET 
In preparation for radiotherapy planning, an FDG-PET/CT scan was performed on a Siemens 
Biograph mCT (Siemens Healthineers, Erlangen), on a flat table top in treatment position 
approximately 60 min after FDG injection (4MBq/kg). An iodine-based contrast medium was 
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injected intravenously during the CT scan according to departmental guidelines.  Details on PET 
and CT data acquisition from our institution is previously published13. A maximum of five lesions 
per patient were evaluated (Two T-sites/three N-sites). If a patient had multiple FDG avid lesions, 
the five lesions with the highest FDG uptake and the largest diameter were chosen. FDG avid 
lesions were contoured with region of interest (ROI)s drawn semi-automatically using a threshold 
of 50 % of the maximum standardized uptake value (SUV max). SUVmax, SUVpeak, SUVmean and 
volume (cm3) were calculated for all individual FDG positive lesions. SUVpeak is defined 
according to the PERCIST criteria14 as a sphere of 1 cm3 centering the hottest point in the lesion. 
The total lesion glycolysis (TLG) is defined as volume x SUVmean. If a primary tumor (T-site) could 
not be separated from affected lymph nodes (N-site), the lesion was analyzed as a T-site lesion. 
Data from the PET scan was analyzed on a Mirada XD® workstation (version 1.1.0.31).  
Radiotherapy  
Radiotherapy was given in 2 Gy fractions, five fractions per week to a total of 60-66 Gy.  3D 
conformal (until January 2014) or volumetric modulated arc therapy (VMAT) planning techniques 
were applied and based on the midventilation phase of a 4D CT15. Cone beam CT with tumor match 
were used for daily image guidance.  
The study was approved by the Danish Health and Medicines Authority, case no 3-3013-569/1/ and 
complied with national data protection regulations.  According to Danish law, no research ethics 
approval was necessary due to the retrospective nature of the study. 
Statistics and data analysis 
Wilcoxon-Mann-Whitney U tests were used for comparison of ordinal or continuous baseline 
clinical data in AC versus SCC patients. The chi square test was used to test for associations 
between two categorical variables, Table 1.  
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Date of histology-confirmed diagnosis was used as the start date, and the date of imaging (CT, FDG 
PET or MR scans) confirming a relapse/progression, was used as failure dates. The time interval 
between the start date and the earliest radiologically confirmed treatment failure was defined as time 
to first failure (TFF). Patients alive with no evidence of disease (NED) were censored at the last 
follow-up in the clinic. Overall survival (OS) and TFF data was analyzed using Kaplan Meier 
plots16 and univariate Cox regression. IBM® SPSS Statistics for Windows, Version 21.0 (Armonk, 
NY: IBM Corp) was used for these analyses.  
First site of failure was specified as Tumor-site (T-site) local failure (LF), lymph node (N-site) 
regional failure (RF), distant metastases, either extra-cranial (ECDM) or intra-cranial (ICDM). 
Failure within the thorax but outside the radiotherapy planning target volume (PTV) was scored as 
ECDM. In case of synchronous local and distant failure, the patient was scored as failing distantly 
(ECDM or ICDM).  Patients with loco-regional failure were scored on a lesion level regarding T 
versus N site lesions and the lesion SUVpeak value from the radiotherapy planning scan was 
calculated for subsequent statistical analysis. 
Failure sites in adenocarcinoma and squamous cell carcinoma were compared in univariate 
competing risk modeling. The cuminc function of the CMPRSK package (version 2.2.7) was used 
to compare the groups with Fine and Gray’s test.  
A statistical plan was made prior to the multivariate cox regression analysis. Coding and variables 
are listed in Table 2. The variables were preselected to reflect a parsimonious list of clinical 
prognosticators. Subsequent to data collection changes were made by excluding TLG measures due 
to strong correlation with GTV and SUVpeak yielding unstable models, supplementary Figure 1. 
SUVpeak was chosen prior to seeing the data due to its use in the PERCIST guidelines
14.  Also, 
smoking status in pack-years was excluded as there was no sign of prognostic value (log rank 
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p=0.43 for trend between tertiles) in the current data set. The exclusion of smoking status avoided 
the complication of imputing six cases with missing data on smoking history. 
In all cases the model was stratified for the use of concomitant platinum based chemotherapy. In 
multivariate modeling, ECDM and ICDM were combined to "DM" for power and interpretability of 
the electronic nomogram. Cause specific Cox multivariate regression was performed using the CSC 
function of the RiskRegression package, version 1.4.3  in R17.  
Lesion level analysis 
Multivariable logistic regression analysis was applied to all lesions in patients with known loco-
regional failure. Two variables on lesion specific outcome were included in the analysis: SUVpeak 
and tumor versus node (TvsN) (categorical variable T=1, N=0).  
 
𝑃 =
exp(𝑏0 + 𝑏1∗𝑥 𝑇𝑣𝑠𝑁 + 𝑏2∗𝑥𝑆𝑈𝑉𝑝𝑒𝑎𝑘)
1 + exp(𝑏0 + 𝑏1∗𝑥 𝑇𝑣𝑠𝑁 + 𝑏2∗𝑥𝑆𝑈𝑉𝑝𝑒𝑎𝑘)
 
 
where P is the probability of being first site of failure in the group of patients with known LRF. We 
interpret P as the conditional failure probability of a lesion, given loco-regional failure. This 
conditional failure probability, P, is subsequently multiplied by the absolute risk of loco-regional 
failure from the competing risk analysis to yield individual lesion failure risk at RT planning 
PET/CT. Thus, the probability of lesion failure, predicted at the time of RT planning, is calculated 
by multiplying P with the risk of loco-regional failure after 24 months according to the competing 
risk model. 
Model calibration was assessed by plotting the lesion predicted probability against observed 
probability in 8 quantiles.  
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The risk models were published as web applications18 at http://bit.ly/LungModel, 
http://bit.ly/LungModelGTV and http://bit.ly/LungModelFDG using the R statistical software 
package "shiny". We used logistic regression of observed failures vs. predicted risk of lesion failure 
to estimate the uncertainty of predictions and provide +/- 1.96 times the standard error of the 
logistic fit as estimate of the uncertainty of the lesion failure probability in the web applications. 
RESULTS 
 
Treatment response and follow-up 
In this retrospective study 251 patients, of 376 patients screened, were included. The eligibility 
criteria were: retrievable radiotherapy planning PET/CT scans (5 patients excluded); receiving 
curative intent radiotherapy (39 patients excluded); available medical records (15 patients 
excluded); histology of AC or SCC (49 patients excluded), and with FDG PET positive lesions to 
analyze (17 patients excluded). Patient characteristics are shown in Table 1.  
Missing data were handled as follows. Performance status (PS) was missing in seven patients but 
could be retrospectively assessed from electronic file information. Gross tumor volume (GTV) was 
missing in two patients. A specialist in lung cancer radiology contoured these GTVs retrospectively. 
Eighteen patients had initial stage IV disease, eleven of which had M1a disease. These lesions 
received curative intended radiotherapy. Five patients had brain metastases that were either 
surgically removed or had stereotactic radiotherapy prior to curative intended therapy of the lung 
lesions. Two patients had M1b disease due to metastases to 1) the adrenal gland and 2) a target in 
the left breast region. These targets were treated with a stereotactic dose and up to 34 Gy, 
respectively. Outliers in patient characteristics were age with AC having a larger fraction of 
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younger patients than SCC. T-stage also showed a slight imbalance between the groups, 
supplementary Figures 2 and 3.  
 
 
Three patients relapsed in new lymph nodes inside the thorax but outside the PTV. Six patients 
failed loco-regionally with LN failure outside the thorax (neck, axilla, below the diaphragm). These 
nine patients were coded with ECDM as first site of failure.  
Seven patients relapsed inside the thorax but outside the PTV, e.g. contralateral lung (M1a disease) 
and were coded ECDM. Two of them had other distant metastases (bone and pleura). Seven T-site 
failures and four N-site failures also failed in distant sites and were scored as distant metastases. See 
supplementary Table 1 for distribution of first failure sites in AC versus SCC. 
 
Median time from diagnosis to first relapse was 10.5 months and median time from first relapse to 
death was 6 months. Overall survival was median 18 months for the whole group of 251 patients 
with no difference in the two histology groups, HR 0.84, 95% CI [0.62; 1.15]. TFF in the two 
histology groups were equal, median time 12 months, HR 1.23, 95% CI [0.90; 1.67]. Patients 
receiving cCRT versus sequential therapy did not have significantly longer OS, HR 1.11, 95% CI 
[0.81; 1.52]. 
Competing risk analysis 
Competing risk analysis found a strong association between relapse patterns and histology. AC had 
lower risk of failing LRF compared to SCC, HR 0.45, 95% CI [0.26; 0.76], p= 0.003. The risk of 
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failing distantly was twice as high in the AC group, HR 2.21, 95% CI [1.41; 3.48], p< 0.001. See 
Table 2.  
Figure 1 shows the risk of various first-failure types from the competing risk model. The risk of an 
event increases with time but no major change in risk from two to three years since most failures 
occur within the first 24 months.   
Stacked patient level outcome shows by Fine and Grey test, AC to have a higher rate of ICDM, 
p=0.00014 and ECDM, p= 0.04 compared to SCC. SCC tend to fail loco-regionally more often than 
AC, p=0.0002. There was no difference in Death, NED, p=0.18, see Figure 2. 
 Lesion risk assessment 
Among the 251 patients, 517 lesions were registered with FDG PET uptake from the radiotherapy 
planning PET/CT scan. Seventy-six lesions (15%) failed in local or regional sites with 60 T-site 
failures and 16 N-site failures. Logistic regression showed SUVpeak and TvsN to be predictors of 
lesion failure. T-site lesions were >12 times more likely to fail than N-site lesions, OR 12.8; 95% 
CI [5.10; 32.17], p= <0.0001. Increasing SUVpeak was associated with an increased likelihood of 
lesion failure, OR 1.26; 95% CI [1.12; 1.40], p<0.0001.  
We found and analyzed 245 FDG avid lymph nodes, up to three lymph nodes per patient. Of these 
FDG avid N-site lesions 168 lesions (68.6%) were biopsy proven malignant. Lymph node stations 
4, 7 and 10 were predominantly represented. Twenty N-site lesions with corresponding positive 
biopsies relapsed. 238 patients with a total of 493 lesions were included in the overall predicted 
lesion failure probability analysis. Thirteen patients with no T-site but with 24 nodal lesions were 
excluded from this analysis. Figure 3 illustrates two patients with different histology and thus 
difference in lesion failure assessment based on the combined lesion failure probability analysis. 
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The lesion model check was performed and showed agreement between calculated risk and actual 
failure on a lesion level, Figure 4. 
3. DISCUSSION 
  
We developed a competing risk model able to estimate the patient level risk of LRF, DM and death 
NED. Further, the radiation target was subdivided in individual lesions and the model could predict 
the lesion level risk of failure in the current dataset. Competing risk analysis showed that histology 
was the strongest predictor for LRF versus DM failure. We found T- versus N-site and SUVpeak to 
be predictive of lesion specific outcome in addition to the patient level prognostics. Internal 
consistency of the model was examined and we found reasonable agreement between predicted 
lesion failure probability and actual lesion failure in calibration plots.  
It is of importance that the model is only used for decision support and should be read with caution. 
Results from the model are generated under the assumption that all clinical targets, T-and N-sites, 
are given a homogeneous normo fractionation scheme of 2 Gy times 30-33 times, 5F/W to a total of 
60 to 66 Gy. It should be stressed that an estimate of low risk of lesion failure does not indicate that 
it is safe to reduce the dose or otherwise compromise radiation delivery to that lesion. 
Nevertheless, our results illustrate the importance of differentiating AC and SCC patients since they 
have different relapse patterns. The aggregate term non-small cell lung cancer may not be helpful in 
advancing the field. 
There are numerous reports of the prognostic value of SUVmax of the primary lesion and overall cut-
off values have been suggested to define good versus poor prognosis19,20,21,22. The lack of external 
validation should be acknowledged as a limitation of the current study. A number of externally 
validated prognostic models for overall survival have been published, see for example 
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predictcancer.org. Failure site prognostication as in the current study potentially has, if externally 
validated, additional clinical interest.  
We have previously found support for early lesion-specific PET response (ΔSUVpeak) after one 
series of chemotherapy to be predictive of failure site in tumor versus nodal sites13. A decrease in 
FDG uptake in both tumor and lymph nodes after radiotherapy was also found to be a prognostic 
factor for survival and recurrence23. Looking at subvolumes within the original T-site, other authors 
have found that high SUV values could identify areas of high local failure risk24,25. This led to 
studies investigating dose-escalation to these areas hoping to achieve a better local tumor 
control26,27.  
When analyzing FDG uptake in lymph nodes28, a risk of false positive findings must be taken into 
consideration. The rate of false positive lymph node lesions cannot be extracted from our data. SUV 
measurements varies by glucose blood levels, acquisition modes and reconstruction algorithms of 
the PET scans which makes data hard to reproduce and define a definitive cut-off value that is 
prognostic of outcome in a cancer population. An external validation of our findings should be 
conducted to confirm the rationale in differentiating between histology groups and lesion 
characteristics and a prospective study could ideally validate our findings of lesion specific risk 
prediction.  
Improved estimates of the probability of these competing risks will allow individual treatment 
approaches that would target the patient’s most likely failure type if managed with current standard 
therapy. The need for such personalized patient selection is particularly evident after the impairment 
in survival observed for patients in the experimental RT arm of RTOG061712, possibly due to 
excess mortality as a result of the aggressive local treatment intensification.  Future randomized 
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trials of local radiotherapy intensification are encouraged to distinguish upon histology and risks of 
competing events upon inclusion.  
In conclusion, adenocarcinoma and squamous cell carcinoma of the lung differ in patterns of first 
failure site after definitive chemo-radiotherapy. Competing risk estimates of DM, LRF and death 
NED were generated. Moreover, it was possible to estimate risk of failure in sub-lesions of the 
radiation target based on lesion site, SUVpeak and patient level clinical variables. 
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 30 
Introduction 31 
The aim of the study was to build a model of first failure site and lesion specific failure probability 32 
after definitive chemo-radiotherapy for inoperable non-small cell lung cancer (NSCLC).  33 
Methods 34 
We retrospectively analyzed 251 patients receiving definitive chemo/radiotherapy for NSCLC at a 35 
single institution between 2009-2015. All patients were FDG PET/CT scanned for radiotherapy 36 
planning. Clinical patient data and FDG PET standardized uptake values from primary tumor and 37 
nodal lesions were analyzed using multivariate cause-specific Cox regression. In patients 38 
experiencing loco-regional failure, multivariable logistic regression was applied to assess risk of 39 
each lesion being first site of failure. The two models were used in combination to predict lesion 40 
failure probability accounting for competing events. 41 
Results 42 
Adenocarcinoma had a lower hazard ratio (HR) of loco-regional (LR) failure than squamous cell 43 
carcinoma, HR 0.45, 95% CI [0.26; 0.76], p =0.003. Distant failures were more common in the 44 
adenocarcinoma group, HR 2.21, 95% CI [1.41; 3.48], p<0.001. Multivariable logistic regression of 45 
individual lesions at the time of first failure showed primary tumors were more likely to fail than 46 
lymph nodes, OR 12.8, 95% CI [5.10; 32.17], p<0.001. Increasing SUVpeak was significantly 47 
associated with lesion failure, OR 1.26 per unit increase, 95% CI [1.12; 1.40], p<0.001. Electronic 48 
model: http://bit.ly/LungModelFDG. 49 
Conclusions  50 
We developed a failure-site specific competing risk model based on patient- and lesion-level 51 
characteristics. Failure patterns differed between adenocarcinoma and squamous cell carcinoma, 52 
illustrating the limitation of aggregating them into 'non-small-cell lung cancer'. Failure site specific 53 
models add complementary information to conventional prognostic models.  54 
 55 
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1. INTRODUCTION 74 
 75 
Curative intended chemo-radiotherapy has long been standard of care for inoperable non-small cell 76 
lung cancer patients1. Local or distant progression is frequently seen after therapy, but also death 77 
due to competing events is relatively frequent. Despite advances in targeted therapy for a subset of 78 
patients with relatively rare genetic mutations, five-year overall survival rates remain 79 
unsatisfactory, around 15% 2,3. The natural course of disease depends on histology, with 80 
adenocarcinoma (AC)  metastasizing to the brain more often than squamous cell carcinoma (SCC) 81 
4,5,6,7. Nevertheless, adenocarcinoma and squamous cell carcinoma are often lumped together as 82 
'non-small-cell lung cancer' in clinical trials or treatment guidelines. 83 
The Union for International Cancer Control (UICC) TNM  classifications8,9 provide important 84 
prognostic information.  However, when deciding on a combination of systemic and local therapies, 85 
estimating the risk of loco-regional versus distant recurrence separately would be of obvious 86 
clinical interest. Other factors such as tumor volume and number of fluoro-deoxy-glucose/positron 87 
emission tomography (FDG-PET) positive lymph nodes have been proposed to improve the pre-88 
treatment prognostic assessment10,11.   89 
Clinical radiotherapy trials have tested dose escalation to the primary lung tumor in an attempt to 90 
improve local control and in turn overall survival. However, the large RTOG 0617 randomized 91 
trial12 found no clinical benefit  in the dose-escalation arm emphasizing that local intensification 92 
may not be a viable strategy for all NSCLC patients. Improved knowledge of the most likely failure 93 
sites within a patient may be of relevance for further individualization of treatment options in the 94 
future.  95 
 96 
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The aim of the current study was to establish a model of the failure patterns on a patient and lesion 97 
level using baseline clinical data and FDG-PET/ computed tomography (CT) scans.  98 
2. MATERIALS AND METHODS 99 
 100 
Patients 101 
 102 
Data were retrospectively retrieved from medical records and archived scans from consecutive 103 
patients diagnosed with inoperable, locally advanced NSCLC and treated at Rigshospitalet, 104 
Copenhagen University Hospital from January 2009 to February 2015. In this time period, 105 
operability was determined according to clinical stage below IIIAN2, co-morbidity of the patient 106 
and lung function by a multidisciplinary tumor board consisting of pulmonologists, thoracic 107 
surgeons and medical/radiation oncologists. Patients received definitive chemo/radiotherapy or 108 
radiotherapy alone. Chemotherapy was either given sequentially prior to radiation or concomitantly 109 
with the first cycle of chemotherapy prior to the PET/CT planning scan. Chemotherapy regimens 110 
consisted of either cisplatin/vinorelbin or carboplatin/vinorelbin in a three-week schedule, given 111 
three to six times. Patients with prior early-stage lung cancer treated with surgery but now 112 
candidates for concomitant chemo/radiotherapy (cCRT) were also included in the study. This could 113 
for example be due to relapse in a lymph node station or a new primary tumor These patients were 114 
restaged according to the 7th TNM classification from UICC8.  115 
FDG-PET 116 
In preparation for radiotherapy planning, an FDG-PET/CT scan was performed on a Siemens 117 
Biograph mCT (Siemens Healthineers, Erlangen), on a flat table top in treatment position 118 
approximately 60 min after FDG injection (4MBq/kg). An iodine-based contrast medium was 119 
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injected intravenously during the CT scan according to departmental guidelines.  Details on PET 120 
and CT data acquisition from our institution is previously published13. A maximum of five lesions 121 
per patient were evaluated (Two T-sites/three N-sites). If a patient had multiple FDG avid lesions, 122 
the five lesions with the highest FDG uptake and the largest diameter were chosen. FDG avid 123 
lesions were contoured with region of interest (ROI)s drawn semi-automatically using a threshold 124 
of 50 % of the maximum standardized uptake value (SUV max). SUVmax, SUVpeak, SUVmean and 125 
volume (cm3) were calculated for all individual FDG positive lesions. SUVpeak is defined 126 
according to the PERCIST criteria14 as a sphere of 1 cm3 centering the hottest point in the lesion. 127 
The total lesion glycolysis (TLG) is defined as volume x SUVmean. If a primary tumor (T-site) could 128 
not be separated from affected lymph nodes (N-site), the lesion was analyzed as a T-site lesion. 129 
Data from the PET scan was analyzed on a Mirada XD® workstation (version 1.1.0.31).  130 
Radiotherapy  131 
Radiotherapy was given in 2 Gy fractions, five fractions per week to a total of 60-66 Gy.  3D 132 
conformal (until January 2014) or volumetric modulated arc therapy (VMAT) planning techniques 133 
were applied and based on the midventilation phase of a 4D CT15. Cone beam CT with tumor match 134 
were used for daily image guidance.  135 
The study was approved by the Danish Health and Medicines Authority, case no 3-3013-569/1/ and 136 
complied with national data protection regulations.  According to Danish law, no research ethics 137 
approval was necessary due to the retrospective nature of the study. 138 
Statistics and data analysis 139 
Wilcoxon-Mann-Whitney U tests were used for comparison of ordinal or continuous baseline 140 
clinical data in AC versus SCC patients. The chi square test was used to test for associations 141 
between two categorical variables, Table 1.  142 
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Date of histology-confirmed diagnosis was used as the start date, and the date of imaging (CT, FDG 143 
PET or MR scans) confirming a relapse/progression, was used as failure dates. The time interval 144 
between the start date and the earliest radiologically confirmed treatment failure was defined as time 145 
to first failure (TFF). Patients alive with no evidence of disease (NED) were censored at the last 146 
follow-up in the clinic. Overall survival (OS) and TFF data was analyzed using Kaplan Meier 147 
plots16 and univariate Cox regression. IBM® SPSS Statistics for Windows, Version 21.0 (Armonk, 148 
NY: IBM Corp) was used for these analyses.  149 
First site of failure was specified as Tumor-site (T-site) local failure (LF), lymph node (N-site) 150 
regional failure (RF), distant metastases, either extra-cranial (ECDM) or intra-cranial (ICDM). 151 
Failure within the thorax but outside the radiotherapy planning target volume (PTV) was scored as 152 
ECDM. In case of synchronous local and distant failure, the patient was scored as failing distantly 153 
(ECDM or ICDM).  Patients with loco-regional failure were scored on a lesion level regarding T 154 
versus N site lesions and the lesion SUVpeak value from the radiotherapy planning scan was 155 
calculated for subsequent statistical analysis. 156 
Failure sites in adenocarcinoma and squamous cell carcinoma were compared in univariate 157 
competing risk modeling. The cuminc function of the CMPRSK package (version 2.2.7) was used 158 
to compare the groups with Fine and Gray’s test.  159 
A statistical plan was made prior to the multivariate cox regression analysis. Coding and variables 160 
are listed in Table 2. The variables were preselected to reflect a parsimonious list of clinical 161 
prognosticators. Subsequent to data collection changes were made by excluding TLG measures due 162 
to strong correlation with GTV and SUVpeak yielding unstable models, supplementary Figure 1. 163 
SUVpeak was chosen prior to seeing the data due to its use in the PERCIST guidelines
14.  Also, 164 
smoking status in pack-years was excluded as there was no sign of prognostic value (log rank 165 
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p=0.43 for trend between tertiles) in the current data set. The exclusion of smoking status avoided 166 
the complication of imputing six cases with missing data on smoking history. 167 
In all cases the model was stratified for the use of concomitant platinum based chemotherapy. In 168 
multivariate modeling, ECDM and ICDM were combined to "DM" for power and interpretability of 169 
the electronic nomogram. Cause specific Cox multivariate regression was performed using the CSC 170 
function of the RiskRegression package, version 1.4.3  in R17.  171 
Lesion level analysis 172 
Multivariable logistic regression analysis was applied to all lesions in patients with known loco-173 
regional failure. Two variables on lesion specific outcome were included in the analysis: SUVpeak 174 
and tumor versus node (TvsN) (categorical variable T=1, N=0).  175 
 176 
𝑃 =
exp(𝑏0 + 𝑏1∗𝑥 𝑇𝑣𝑠𝑁 + 𝑏2∗𝑥𝑆𝑈𝑉𝑝𝑒𝑎𝑘)
1 + exp(𝑏0 + 𝑏1∗𝑥 𝑇𝑣𝑠𝑁 + 𝑏2∗𝑥𝑆𝑈𝑉𝑝𝑒𝑎𝑘)
 178 
 177 
where P is the probability of being first site of failure in the group of patients with known LRF. We 179 
interpret P as the conditional failure probability of a lesion, given loco-regional failure. This 180 
conditional failure probability, P, is subsequently multiplied by the absolute risk of loco-regional 181 
failure from the competing risk analysis to yield individual lesion failure risk at RT planning 182 
PET/CT. Thus, the probability of lesion failure, predicted at the time of RT planning, is calculated 183 
by multiplying P with the risk of loco-regional failure after 24 months according to the competing 184 
risk model. 185 
Model calibration was assessed by plotting the lesion predicted probability against observed 186 
probability in 8 quantiles.  187 
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The risk models were published as web applications18 at http://bit.ly/LungModel, 188 
http://bit.ly/LungModelGTV and http://bit.ly/LungModelFDG using the R statistical software 189 
package "shiny". We used logistic regression of observed failures vs. predicted risk of lesion failure 190 
to estimate the uncertainty of predictions and provide +/- 1.96 times the standard error of the 191 
logistic fit as estimate of the uncertainty of the lesion failure probability in the web applications. 192 
RESULTS 193 
 194 
Treatment response and follow-up 195 
In this retrospective study 251 patients, of 376 patients screened, were included. The eligibility 196 
criteria were: retrievable radiotherapy planning PET/CT scans (5 patients excluded); receiving 197 
curative intent radiotherapy (39 patients excluded); available medical records (15 patients 198 
excluded); histology of AC or SCC (49 patients excluded), and with FDG PET positive lesions to 199 
analyze (17 patients excluded). Patient characteristics are shown in Table 1.  200 
Missing data were handled as follows. Performance status (PS) was missing in seven patients but 201 
could be retrospectively assessed from electronic file information. Gross tumor volume (GTV) was 202 
missing in two patients. A specialist in lung cancer radiology contoured these GTVs retrospectively. 203 
Eighteen patients had initial stage IV disease, eleven of which had M1a disease. These lesions 204 
received curative intended radiotherapy. Five patients had brain metastases that were either 205 
surgically removed or had stereotactic radiotherapy prior to curative intended therapy of the lung 206 
lesions. Two patients had M1b disease due to metastases to 1) the adrenal gland and 2) a target in 207 
the left breast region. These targets were treated with a stereotactic dose and up to 34 Gy, 208 
respectively. Outliers in patient characteristics were age with AC having a larger fraction of 209 
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younger patients than SCC. T-stage also showed a slight imbalance between the groups, 210 
supplementary Figures 2 and 3.  211 
 212 
 213 
Three patients relapsed in new lymph nodes inside the thorax but outside the PTV. Six patients 214 
failed loco-regionally with LN failure outside the thorax (neck, axilla, below the diaphragm). These 215 
nine patients were coded with ECDM as first site of failure.  216 
Seven patients relapsed inside the thorax but outside the PTV, e.g. contralateral lung (M1a disease) 217 
and were coded ECDM. Two of them had other distant metastases (bone and pleura). Seven T-site 218 
failures and four N-site failures also failed in distant sites and were scored as distant metastases. See 219 
supplementary Table 1 for distribution of first failure sites in AC versus SCC. 220 
 221 
Median time from diagnosis to first relapse was 10.5 months and median time from first relapse to 222 
death was 6 months. Overall survival was median 18 months for the whole group of 251 patients 223 
with no difference in the two histology groups, HR 0.84, 95% CI [0.62; 1.15]. TFF in the two 224 
histology groups were equal, median time 12 months, HR 1.23, 95% CI [0.90; 1.67]. Patients 225 
receiving cCRT versus sequential therapy did not have significantly longer OS, HR 1.11, 95% CI 226 
[0.81; 1.52]. 227 
Competing risk analysis 228 
Competing risk analysis found a strong association between relapse patterns and histology. AC had 229 
lower risk of failing LRF compared to SCC, HR 0.45, 95% CI [0.26; 0.76], p= 0.003. The risk of 230 
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failing distantly was twice as high in the AC group, HR 2.21, 95% CI [1.41; 3.48], p< 0.001. See 231 
Table 2.  232 
Figure 1 shows the risk of various first-failure types from the competing risk model. The risk of an 233 
event increases with time but no major change in risk from two to three years since most failures 234 
occur within the first 24 months.   235 
Stacked patient level outcome shows by Fine and Grey test, AC to have a higher rate of ICDM, 236 
p=0.00014 and ECDM, p= 0.04 compared to SCC. SCC tend to fail loco-regionally more often than 237 
AC, p=0.0002. There was no difference in Death, NED, p=0.18, see Figure 2. 238 
 Lesion risk assessment 239 
Among the 251 patients, 517 lesions were registered with FDG PET uptake from the radiotherapy 240 
planning PET/CT scan. Seventy-six lesions (15%) failed in local or regional sites with 60 T-site 241 
failures and 16 N-site failures. Logistic regression showed SUVpeak and TvsN to be predictors of 242 
lesion failure. T-site lesions were >12 times more likely to fail than N-site lesions, OR 12.8; 95% 243 
CI [5.10; 32.17], p= <0.0001. Increasing SUVpeak was associated with an increased likelihood of 244 
lesion failure, OR 1.26; 95% CI [1.12; 1.40], p<0.0001.  245 
We found and analyzed 245 FDG avid lymph nodes, up to three lymph nodes per patient. Of these 246 
FDG avid N-site lesions 168 lesions (68.6%) were biopsy proven malignant. Lymph node stations 247 
4, 7 and 10 were predominantly represented. Twenty N-site lesions with corresponding positive 248 
biopsies relapsed. 238 patients with a total of 493 lesions were included in the overall predicted 249 
lesion failure probability analysis. Thirteen patients with no T-site but with 24 nodal lesions were 250 
excluded from this analysis. Figure 3 illustrates two patients with different histology and thus 251 
difference in lesion failure assessment based on the combined lesion failure probability analysis. 252 
 253 
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The lesion model check was performed and showed agreement between calculated risk and actual 254 
failure on a lesion level, Figure 4. 255 
3. DISCUSSION 256 
  257 
We developed a competing risk model able to estimate the patient level risk of LRF, DM and death 258 
NED. Further, the radiation target was subdivided in individual lesions and the model could predict 259 
the lesion level risk of failure in the current dataset. Competing risk analysis showed that histology 260 
was the strongest predictor for LRF versus DM failure. We found T- versus N-site and SUVpeak to 261 
be predictive of lesion specific outcome in addition to the patient level prognostics. Internal 262 
consistency of the model was examined and we found reasonable agreement between predicted 263 
lesion failure probability and actual lesion failure in calibration plots.  264 
It is of importance that the model is only used for decision support and should be read with caution. 265 
Results from the model are generated under the assumption that all clinical targets, T-and N-sites, 266 
are given a homogeneous normo fractionation scheme of 2 Gy times 30-33 times, 5F/W to a total of 267 
60 to 66 Gy. It should be stressed that an estimate of low risk of lesion failure does not indicate that 268 
it is safe to reduce the dose or otherwise compromise radiation delivery to that lesion. 269 
Nevertheless, our results illustrate the importance of differentiating AC and SCC patients since they 270 
have different relapse patterns. The aggregate term non-small cell lung cancer may not be helpful in 271 
advancing the field. 272 
There are numerous reports of the prognostic value of SUVmax of the primary lesion and overall cut-273 
off values have been suggested to define good versus poor prognosis19,20,21,22. The lack of external 274 
validation should be acknowledged as a limitation of the current study. A number of externally 275 
validated prognostic models for overall survival have been published, see for example 276 
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predictcancer.org. Failure site prognostication as in the current study potentially has, if externally 277 
validated, additional clinical interest.  278 
We have previously found support for early lesion-specific PET response (ΔSUVpeak) after one 279 
series of chemotherapy to be predictive of failure site in tumor versus nodal sites13. A decrease in 280 
FDG uptake in both tumor and lymph nodes after radiotherapy was also found to be a prognostic 281 
factor for survival and recurrence23. Looking at subvolumes within the original T-site, other authors 282 
have found that high SUV values could identify areas of high local failure risk24,25. This led to 283 
studies investigating dose-escalation to these areas hoping to achieve a better local tumor 284 
control26,27.  285 
When analyzing FDG uptake in lymph nodes28, a risk of false positive findings must be taken into 286 
consideration. The rate of false positive lymph node lesions cannot be extracted from our data. SUV 287 
measurements varies by glucose blood levels, acquisition modes and reconstruction algorithms of 288 
the PET scans which makes data hard to reproduce and define a definitive cut-off value that is 289 
prognostic of outcome in a cancer population. An external validation of our findings should be 290 
conducted to confirm the rationale in differentiating between histology groups and lesion 291 
characteristics and a prospective study could ideally validate our findings of lesion specific risk 292 
prediction.  293 
Improved estimates of the probability of these competing risks will allow individual treatment 294 
approaches that would target the patient’s most likely failure type if managed with current standard 295 
therapy. The need for such personalized patient selection is particularly evident after the impairment 296 
in survival observed for patients in the experimental RT arm of RTOG061712, possibly due to 297 
excess mortality as a result of the aggressive local treatment intensification.  Future randomized 298 
14 
 
trials of local radiotherapy intensification are encouraged to distinguish upon histology and risks of 299 
competing events upon inclusion.  300 
In conclusion, adenocarcinoma and squamous cell carcinoma of the lung differ in patterns of first 301 
failure site after definitive chemo-radiotherapy. Competing risk estimates of DM, LRF and death 302 
NED were generated. Moreover, it was possible to estimate risk of failure in sub-lesions of the 303 
radiation target based on lesion site, SUVpeak and patient level clinical variables. 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
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record and begin the revision process. 
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Dirk De Ruysscher 
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Reviewer Comments: 
 
Reviewer #1: The authors have presented a well written and original manuscript building a 
model of first failure site and lesion specific probability after definitive chemo-radiotherapy for 
inoperable NSCLC. The discussion and interpretations is careful performed and contains the 
limitations of the study. I enjoyed the assessment of each seperate lesion within one patient 
and the conclusion that adenocarcinoma's and SCC should not be dealt with as the same 
disease. 
 
Comments: 
1) 251 patients were included, a minority (n=10) had a local recurrence after VATS surgery. 
Would it not be better to exclude these patients to form a more homogenous group of 'first 
treatment'? 
This is something we discussed extensively in our group when planning the data analysis. 
Patients treated at our clinic present with diverse histories, as is customary for NSCLC, and we 
decided to prioritize an unselected ‘real life’ cohort of SCC and AC rather than excluding more 
patients. 
 
2) Patients were all diagnosed with inoperable NSCLC. How many medical inoperable (WHO 
score was 0 in 61%), how many oncological inoperable? What is considered as oncological 
inoperable in your centre? IIIAN2 in general, single level disease, multilevel disease? 
Patient cases are presented at multidisciplinary tumor boards which consist of pulmonologists, 
thoracic surgeons, medical/radiation oncologists and pathologists. Here it is decided which 
treatment the patient is offered taking histology, performance status, co-morbidity, UICC stage 
and lung function into consideration. In general, IIIAN2 was considered a multilevel disease 
and oncologically inoperable during the time period covered by our study. Recently, however, 
it is becoming increasingly common to consider operation on these patients. We have 
modified the manuscript to make our practice clearer as follows……  
page 5: “In this time period, operability was determined according to clinical stage below 
IIIAN2, co-morbidity of the patient and lung function by a multidisciplinary board 
consisting of pulmonologists, thoracic surgeons and medical/radiation oncologists. 
 
3) Some abbreviations are not explained to the reader: ROIs , TvsN 
Thank you. This is corrected in the manuscript: page 6: ROIs (region of interest)., page 8: TvsN 
(tumor versus node)  
 
4) A maximum of five lesions per patient were evaluated (2 T , 3 N sites) Where patients with 
more lesions excused? If not, how did you select the lesions? 
Patients with multiple lesions, the five lesions were selected as follows:  
T1 and T2 (primary tumor and a potential satellite tumor). If more than 1 satellite tumor, the 
lesion with the highest FDG uptake and the largest diameter was chosen.  
The same principle for Nodal disease. If more than 3 N-sites, then the three with the largest 
diameter and highest FDG uptake were selected.  
The following sentence has been added on page 6: 
“If a patient had multiple FDG avid lesions, the five lesions with the highest FDG uptake 
and the largest diameter were chosen.” 
 
5) Page 6There is a ", " missing between SUV peak and SUV mean 
Thank you, this is corrected 
 6) Page 7 In general, I have a problem with the fact that "failure within the thorax but outside 
the radiotherapy PTV is considered a distant metastasis. Ipsilateral recurrence in pleura and 
lymph nodes or same lobe as primary tumor should be considered as local recurrence even if 
not in the PTV. I understand that only 7 patients had recurrence in the thorax outside PTV. 
We are very well aware that the definition of failure within the thorax but outside the PTV is 
debatable. We cannot include a third type of failure (regional failure) in the model as there are 
only 7 of these events. In this study we focus on lesion failure probability prediction and 
classifying failures outside PTV as ‘local’ is problematic for the following reasons; these lesions 
were obviously subclinical (and in particular FDG PET negative) when planning radiotherapy 
and it is thus not meaningful to include them in an analysis of lesion-specific failure 
probability. If the model should work in future studies where one wishes to treat the lesion at 
highest risk with e.g. dose-escalation and the low risk lesions with e.g. normo-fractionation or 
standard dose, this is not feasible for lesions that aren’t visible from the beginning and 
therefore not meaningful to “treat in advance”.   We have therefore chosen to retain the 
definition in this study. In future studies with more power, it should ideally be separated as a 
distinct mode of failure. 
 
7) Page 8: Lesion level analysis. Can you comment why multivariate (multivariable is preferred 
over multivariate if there is a single outcome variable) logistic regression analysis is only 
applied to the lesions in patients with known locoregional failure? In comparison, when 
performing a multivariable regression for death, you would not exclude the survivors? 
1: We changed ‘multivariate to multivariable’ in the logistic regression analysis.  
2: The reason for applying the logistic regression analysis in all lesions within patients failing 
locoregionally is to derive the _conditional_ probability of lesion failure given locoregional 
failure. This is multiplied with the probability of failing locoregionally from the competing risk 
analysis to yield the baseline probability of lesion failure. In other words we apply the law of 
total probability p(A)=p(A given B)*p(B) with the approximation that most locoregional failures 
are seen within 24 months. We have modified the methods section to clarify as follows: …..  
Page 8: “This conditional failure probability, P, is subsequently multiplied by the absolute 
risk of locoregional failure from the competing risk analysis to yield individual lesion failure 
risk at RT planning PET/CT. Thus, the probability of lesion failure, predicted at the time of 
RT planning, is calculated by multiplying P with the risk of loco-regional failure after 24 
months according to the competing risk model.” 
 8) Page 11 and figure 4: Lesion model check: Can you comment why there are only 8 points in 
this chart? 
A rule of thumb is to use sqrt(number of lesion failures) as the number of groups in such plots. 
From experience we rounded down from sqrt(76)=8.7. This decision on grouping was made 
prior to making the calibration plot. 
 
In general, when making a prediction model, one should keep a cohort out of the model 
building to perform a internal validation. Is it correct to state that the same patients were used 
for the model building and model check? If so, this should be in the limitations. 
We agree with the reviewer that sample splitting techniques can be potentially attractive as a 
method for validation, but we consider it as an in-between level; between internal validation 
and external validation if sufficient power is present. In our case, we needed all data in the 
model building to make the prediction model and therefore used the pure internal validation 
of the calibration plot, demonstrating that the model provides a good description on the data, 
but acknowledging the need for (full) external validation as stated in the discussion. We are in 
the process of finding collaborators for external validation of the model 
 
9) References: typo's in ref 18 (specific) and 19 (European Lu...), ref 29 Name missing of VJ 
Thank you. All three references have been corrected. 
 
10) Figure 1: black arrow is missing 
We apologize for the missing arrow. The black arrow is added in the triangle at 3 years (Figure 
1) .  
 
11) Table 1: The total of nodal stage is different from the rest of the manuscript: 
56+20+131+54 equals 261 instead of 251; TX abbrevation unclear in context. 
 
Thank you for your careful revision. There must have been a typo error in N2. We reviewed the 
data and the correct number is 121. This is corrected in Table 1.  
 
Nstadie 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid N0 56 22,3 22,3 22,3 
N1 20 8,0 8,0 30,3 
N2 121 48,2 48,2 78,5 
N3 54 21,5 21,5 100,0 
Total 251 100,0 100,0  
 
Furthermore, a careful revision of Table 1 showed another error: T1: AC 25 and T1: SCC: 8. This 
is wrong. It should be T1: AC 26 and T1 SCC 7. This is corrected with added % as suggested by 
reviewer 2. We apologize for this.  
 
Table 1. In legends is added: TX: no primary tumor. 
 
 
Reviewer #2: This is a retrospective study on 251 patients receiving definitive chemoradiation 
for locally advanced non-small cell lung cancer. The aim of this report was to built a model of 
first failure site and the Authors reached the goal finding an useful model for daily practice. 
Even if the argument is not so original because a lot of researchers' group are working on 
predictive model, the solution proposed is rapid and simple and can give some suggestion for 
daily activity. 
Two minor suggestions can be done: 
- In Materials and Method Patients, FDG-PET, Radiotherapy and Statistics are well described. 
Probably could be added a small addendum for chemotherapy regimen (which is however 
described in table 1) 
Thank you for that comment. The data is available in Table 1 and to maintain readability, we 
did not repeat this data in the text. 
 
 
- Table 1 could be ameliorated adding the percentage values also for AC and SCC 
This is true, thank you. Percentage values for AC and SCC are added to Table 1.  
 
Table 1  
Patient and Treatment Characteristics 
 
 
 
Total 
(N=251) 
%  AC SCC P-value 
Age at diagnosis (median and range)   66y[37;89]  64y[37;89] 66y[43;89] 0.01 
      
UICC Clinical stage     0.14 
I 2 1    1 (0.7%) 1 (0.9%)  
II 28 11    15 (10.4%) 13 (12.1%)  
IIIA/IIIB 203 81    113 (78.5%) 90 (84.1%)  
IV 18 7    15 (10.4%) 3 (2.8%)  
      
Tumor-stage               Surgery*     0.03 
TX                         3 1    1 (0.7%) 2 (1.9%)  
T1                                       (4) 33 13    26 (18.1%) 7 (6.5%)  
T2                                       (2) 53 21    29 (20.1%) 24 (22.4%)  
T3                                       (4) 48 19    32 (22.2%) 16 (15.0 %)  
T4 114 45    56 (38.9%) 58 (54.2%)  
      
Nodal-stage     0.38 
N0 56 22    29 (20.1%) 27 (25.2%)  
N1 20 8    10 (6.9%) 10 (9.3%)  
N2 121 48    69 (47.9%) 52 (48.6%)  
N3 54 22    36 (25.0%) 18 (16.8%)  
      
Gender     0.57 
Male 152 61    85 (59%) 67 (63%)  
Female 99 39    59 (41%) 40 (37 %)  
      
Histology      
AC 144 57    144 …  
SCC 107 43    … 107  
      
WHO performance status     0.26 
0 152 60.6    88 (61.1%) 64 (59.8%)  
1 92 36.6    50 (34.7%) 42 (39.3%)  
2 7 2.8    6 (4.2%) 1 (0.9%)   
      
Smoking pack year (median and 
range)  
40 [0;100]    0.43 
(Missing data in 6 patients)      
      
Chemotherapy regimen      
Cisplatin/vinorelbin 144 57    86 (59.7%) 58 (54.2%) 0.38 
Carboplatin/vinorelbin 95 38    53(36.8%) 42 (39.3%)  
No chemotherapy 11 4    5 (3.5%) 6 (5.6%)  
No data available 1 1    0 1  
Concomitant 167 70    97 (69.8%) 70 (70.0%) 0.75 
Response to Reviewers
Sequential 72 30    42 (30.2%) 30 (30.0%)  
      
Radiation dose     0.23 
2 Gy x 30 (60 Gy) 9 3    5 (3.5%) 4 (3.7%)  
2 Gy x 33 (66 Gy) 240 96    137 (95.1%) 103 (96.3%)  
Did not complete (<50 Gy) 2 1    2 (1.4%) 0 (0.0 %)  
 
Target characteristics (Median 
and range) 
AC SCC P-value 
GTV 74.9 [3.0; 802.6] 89.0 [3.4; 664.0] 0.27 
PTV 468.9 [50.5; 1605.4] 493.8 [46.0; 1440.4] 0.70 
SUVpeak_T-site # 10.1 [1.0; 58.8] 11.7 [2.6; 43.3] 0.20 
SUVpeak_N-site # 6.9 [0.9; 37.4] 8.5 [1.3; 28.8] 0.38 
MTV 8.3 [0.3; 111.8] 10.4 [0.2; 97.3] 0.44 
TLG_SUM 82.4 [2.0; 825.9] 93.1 [0.96; 1063.4] 0.27 
 
Table 1. Patient characteristics divided by histology. Categorical variables (Clinical stage, T-stage, 
N-stage, gender, performance status, chemotherapy regime, and radiation dose) were tested by 
Chi-square method (p-values in cursive). Non parametric variables (Age, pack year, and target 
characteristics) were tested by Mann Whitney U test. Significant p-values (p<0.05) are highlighted. 
UICC: The Union for International Cancer Control. AC: Adenocarcinoma. SCC: Squamous cell 
carcinoma. Gy: Gray. GTV: Gross tumor volume. PTV: Planning target volume. MLD: Mean lung 
dose. SUV: Standardized uptake value. TLG: Total lesion glycolysis.* 13 patients without SUV 
uptake in T-site (10 VATS) and 3 TX.  TX: no primary tumor. Patients with VATS surgery before 
definitive radiotherapy with no SUVpeak values in their T-sites are listed with their T-stage prior to 
surgery. # In case of multiple T-site or N-site lesions, the highest value of SUVpeak was chosen. 
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Figure 1. Predicted outcome one, two and three years after diagnosis for 251 patients with adenocarcinoma 
(grey dots) - or squamous cell carcinoma (black dots) of the lung treated at Rigshospitalet from January 
2009 to February 2015.  Each side of the plot corresponds to the probability of a given endpoint. The black 
arrow points to the intersection of lines corresponding to 70% probability of no evidence of disease (Alive or 
dead, NED) – 10% probability of distant metastases (DM), and 20% probability of loco-regional failure 
(LRF).   
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Figure 2.  Competing risk analysis of first failure site depending on histology.  NED: no 
evidence of disease. ECDM: extra cranial distant metastases. ICDM: intracranial distant 
metastases. LRF: loco-regional failure. 
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Figure 3. Illustration of two patients and their lesion failure probabilities.  
Adenocarcinoma: Primary tumor in right lung. Predicted failure probability=20% [9 to 31%] 
Lymph node metastasis in mediastinum. PFP=2% [0 to 5%] 
Squamous cell carcinoma: Primary tumor in left lung. Predicted failure probability=42% [28 to  
56%] 
Lymph node metastasis in mediastinum. PFP=12% [9 to15%] 
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Figure 4. Binominal calibration plot of predicted failure probability on a lesion level and observed 
lesion failure divided into 8 quantiles including 95% confidence intervals.  
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Figure 4
Table 1  
Patient and Treatment Characteristics 
 
 
 
Total 
(N=251) 
%  AC SCC P-value 
Age at diagnosis (median and range)   66y[37;89]  64y[37;89] 66y[43;89] 0.01 
      
UICC Clinical stage     0.14 
I 2 1    1 (0.7%) 1 (0.9%)  
II 28 11    15 (10.4%) 13 (12.1%)  
IIIA/IIIB 203 81    113 (78.5%) 90 (84.1%)  
IV 18 7    15 (10.4%) 3 (2.8%)  
      
Tumor-stage               Surgery*     0.03 
TX                         3 1    1 (0.7%) 2 (1.9%)  
T1                                       (4) 33 13    26 (18.1%) 7 (6.5%)  
T2                                       (2) 53 21    29 (20.1%) 24 (22.4%)  
T3                                       (4) 48 19    32 (22.2%) 16 (15.0 %)  
T4 114 45    56 (38.9%) 58 (54.2%)  
      
Nodal-stage     0.38 
N0 56 22    29 (20.1%) 27 (25.2%)  
N1 20 8    10 (6.9%) 10 (9.3%)  
N2 121 48    69 (47.9%) 52 (48.6%)  
N3 54 22    36 (25.0%) 18 (16.8%)  
      
Gender     0.57 
Male 152 61    85 (59%) 67 (63%)  
Female 99 39    59 (41%) 40 (37 %)  
      
Histology      
AC 144 57    144 …  
SCC 107 43    … 107  
      
WHO performance status     0.26 
0 152 60.6    88 (61.1%) 64 (59.8%)  
1 92 36.6    50 (34.7%) 42 (39.3%)  
2 7 2.8    6 (4.2%) 1 (0.9%)   
      
Smoking pack year (median and 
range)  
40 [0;100]    0.43 
(Missing data in 6 patients)      
      
Chemotherapy regimen      
Cisplatin/vinorelbin 144 57    86 (59.7%) 58 (54.2%) 0.38 
Carboplatin/vinorelbin 95 38    53(36.8%) 42 (39.3%)  
No chemotherapy 11 4    5 (3.5%) 6 (5.6%)  
No data available 1 1    0 1  
Concomitant 167 70    97 (69.8%) 70 (70.0%) 0.75 
Table 1
Sequential 72 30    42 (30.2%) 30 (30.0%)  
      
Radiation dose     0.23 
2 Gy x 30 (60 Gy) 9 3    5 (3.5%) 4 (3.7%)  
2 Gy x 33 (66 Gy) 240 96    137 (95.1%) 103 (96.3%)  
Did not complete (<50 Gy) 2 1    2 (1.4%) 0 (0.0 %)  
 
Target characteristics (Median 
and range) 
AC SCC P-value 
GTV 74.9 [3.0; 802.6] 89.0 [3.4; 664.0] 0.27 
PTV 468.9 [50.5; 1605.4] 493.8 [46.0; 1440.4] 0.70 
SUVpeak_T-site # 10.1 [1.0; 58.8] 11.7 [2.6; 43.3] 0.20 
SUVpeak_N-site # 6.9 [0.9; 37.4] 8.5 [1.3; 28.8] 0.38 
MTV 8.3 [0.3; 111.8] 10.4 [0.2; 97.3] 0.44 
TLG_SUM 82.4 [2.0; 825.9] 93.1 [0.96; 1063.4] 0.27 
 
Table 1. Patient characteristics divided by histology. Categorical variables (Clinical stage, T-stage, 
N-stage, gender, performance status, chemotherapy regime, and radiation dose) were tested by 
Chi-square method (p-values in cursive). Non parametric variables (Age, pack year, and target 
characteristics) were tested by Mann Whitney U test. Significant p-values (p<0.05) are highlighted. 
UICC: The Union for International Cancer Control. AC: Adenocarcinoma. SCC: Squamous cell 
carcinoma. Gy: Gray. GTV: Gross tumor volume. PTV: Planning target volume. MLD: Mean lung 
dose. SUV: Standardized uptake value. TLG: Total lesion glycolysis.* 13 patients without SUV 
uptake in T-site (10 VATS) and 3 TX.  TX: no primary tumor. Patients with VATS surgery before 
definitive radiotherapy with no SUVpeak values in their T-sites are listed with their T-stage prior to 
surgery. # In case of multiple T-site or N-site lesions, the highest value of SUVpeak was chosen. 
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Table 2 
Outcome 1: Loco-regional relapse as first site of failure 
Co-variable Unit HR, p; base model HR, p; Model with 
GTV 
HR, p; Final model 
with SUVpeak 
Age Year 1.00  [0.96;1.03] 1.00  [0.96;1.03] 0.99  [0.96;1.03] 
Histology AC vs SCC 0.44  [0.26;0.75]   
p=0.002 
0.45  [0.27;0.77]   
p=0.003 
0.45  [0.26;0.76], 
p=0.003 
PS PS1 and higher 
vs. PS 0 
1.77  [1.06;2.94]   
p=0.03 
1.73 [1.04;2.89]   
p=0.03 
1.73 [1.03;2.92]   
p=0.04 
Clinical Stage 
III vs. I and II 3.69 [1.15;11.84]   
p=0.03 
3.61 [1.12;11.59] 
P=0.03 
3.13 [0.97;10.08]   
p=0.06 
IV vs. I and II 1.9 [0.31;11.60]   
p=0.49 
1.92 [0.31;11.72]   
p=0.52 
1.70 [0.28;10.40]   
p=0.57 
GTV per 50 cm3 
increase 
NR 1.04  [0.93;1.15]   
p=0.52 
1.02  [0.91;1.15]   
p=0.68 
SUV peak, T-sites  NR NR 1.00  [0.96;1.04]   
p=0.98 
 
Outcome 2: Distant metastases as first site of failure 
Co-variable Unit HR, p; base model HR, p; Model with 
GTV 
HR, p; Model with 
SUVpeak 
Age Year 0.99  [0.97;1.01] 0.99  [0.96;1.01] 0.99  [0.97;1.02] 
Histology AC vs SCC 2.12  [1.37;3.27]   
p<0.001 
2.43  [1.56;3.78]   
p<0.001 
2.21  [1.41;3.48], 
p<0.001 
PS PS1 and higher 
vs. PS 0 
0.84  [0.57;1.25]   
p=0.40 
0.77  [0.52;1.14]   
p=0.20 
0.77  [0.51;1.17]   
p=0.22 
Clinical Stage 
III vs. I and II 1.56 [0.81;3.03]   
p=0.20 
1.34 [0.69;2.63] 
P=0.40 
1.09 [0.54;2.22]   
p=0.80 
IV vs. I and II 3.35 [1.47;7.62]   
p=0.004 
3.22 [1.42;7.31]   
p=0.005 
3.19 [1.37;7.44]   
p=0.007 
GTV per 50 cm3 
increase 
NR 1.16  [1.07;1.26]   
p<0.001 
1.18  [1.09;1.28]   
p<0.001 
SUV peak, N-
sites 
 NR NR 1.03  [1.00;1.06]   
p=0.035 
 
Outcome 3: Dead, NED as first event 
Co-variable Unit HR, p; base model HR, p; Model with 
GTV 
HR, p; Model with 
SUVpeak 
Age Year 1.02  [0.98;1.07] 1.02  [0.98;1.07] 1.02  [0.98;1.07] 
PS PS1 and higher 
vs. PS 0 
1.59  [0.78;3.24]   
p=0.21 
1.59  [0.78;3.24]   
p=0.21 
1.59  [0.75;3.35]   
p=0.22 
Gender Female vs Male 1.07  [0.52;2.20] 
p=0.85 
1.07  [0.52;2.20] 
p=0.85 
1.17  [0.55;2.50] 
p=0.68 
Table 2
 
Table 2. Sub distribution of hazard ratios in competing risk models. Loco-regional or Distant metastases as 
first site of failure. Dead, NED as first event.  AC: Adenocarcinoma. SCC: Squamous cell carcinoma. HR:  
hazard ratio, P: P-value, <0.05 is significant. NR: not relevant. GTV: Gross tumor volume. PS: Performance 
Status. SUVpeak: Standardized Uptake Value. T-sites: Tumor sites. N-sites: Lymph nodes. NED: No 
evidence of disease. 
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